For more than 30 years now, the name URSAPHARM has stood for the consistent transfer of innovative pharmaceutical concepts into successful medicinal products and medical devices. Today, URSAPHARM is a international operating medium-sized company, headquartered in Saarbrücken and ranks among the market leaders in ophthalmology in Germany. Special focus is placed on the treatment of the dry-eye syndrome (Sicca syndrome). URSAPHARM was the first to discover and explore the need to eliminate potentially harmful preservatives from multidose units of ophtalmological solutions. Medicinal products for use in general medicine complete the portfolio of URSAPHARM, like the enzyme preparation Bromelain-POS® for edema treatment.
Year of foundation1974
Business activityPharmazeutischer Hersteller,
und allgemeinmedizinische Präparate,
Business activityFrank Holzer